OMEICOS Therapeutics GmbH - Management


Dr. Ulrich Dauer Ulrich Dauer, Dr. rer. nat., CEO

Ulrich has longterm professional experience in the biotechnology and pharmaceutical industries. Prior to joining OMEICOS, in his role as Chief Strategy Officer at Activaero GmbH, he was responsible for strategy, growth and financing, and he led the successful negotiations and sale of the company to Vectura Group plc for EUR 130 million in 2014. Prior to that, Dr. Dauer held the position of Chief Executive Officer at 4SC AG, a German biotech company developing small-molecule drugs for the treatment of cancer and autoimmune diseases, where he oversaw multiple licensing and development transactions in addition to raising EUR 150 million in private and public capital, including the company's IPO within the Prime Standard segment of Deutsche Börse.
Dr. Robert Fischer Robert Fischer, Dr. med., CSO
Robert is a board certified medical doctor in Internal Medicine and worked as a clinical cardiologist at the Charité Berlin. He has longterm professional experience as principle investigator and sub-investigator in several cardiovascular clinical trials. To understand the molecular mechanisms underlying cardiac diseases, Robert also focused in his career on basic research. At Max-Delbrueck-Center for Molecular Medicine, he headed a research group and established methods to analyze arrhythmia mechanisms in animal models. In 2013, he founded OMEICOS together with scientists from the MDC Berlin and the UT Southwestern Dallas.
Dr. Karen Uhlmann Karen Uhlmann, Dr. rer. nat., RTTP, Director Legal Corporate & Operations

Karen obtained a dual education as a scientist as well as in business matters. Karen holds a Master and a PhD in Biology from Freie Universität zu Berlin and Humboldt-Universität zu Berlin, respectively. She earned a business degree from the Chamber of Commerce Berlin and is a Recognized Technology Transfer Professional from ATTP. Combining in depth knowledge of both science and business, Karen has been working in the field of life science IP asset and innovation management since 2002. For Ascenion GmbH and its academic partners she successfully set the contractual and business framework for more than 100 innovative technologies, leading to multiple license agreements, funding grants, and collaborations between industry and academia. Before joining OMEICOS, Karen and the scientists of Max-Delbrueck-Center have been working closely together to spin-out OMEICOS’ promising technology.
Luciana Summo, Ph.D. Luciana Summo, Ph.D., Director Clinical Operations

Luciana has more than 15 years experience in the management of clinical studies ranging from phase 1 to phase 3, in different indications spanning cardiovascular, haematology, antiviral, and ophthalmic drug development programs. She has collected her work experience in both big pharma and biotech companies. Prior to joining OMEICOS, she has worked for the Pharma Company Berlin-Chemie/ Menarini Research for 10 years as Clinical Study Manager and afterwards for the biotechnology company NOXXON Pharma AG as Senior Study Manager, covering all operational activities related to all clinical studies of the assigned multi-national clinical development program. Following her degree in Pharmaceutical Chemistry and Technology in 1996 at the University of Bari (I), Luciana obtained her PhD in Medicinal Chemistry (2000) in collaboration with the Institute of Pharmaceutical Science of the King's College in London.